Invention Grant
US08691231B2 Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
有权
主要表达高亲和力EGFR配体或主要表达低亲和力EGFR配体的肿瘤的单克隆抗体和寡克隆抗EGFR抗体的治疗方法
- Patent Title: Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
- Patent Title (中): 主要表达高亲和力EGFR配体或主要表达低亲和力EGFR配体的肿瘤的单克隆抗体和寡克隆抗EGFR抗体的治疗方法
-
Application No.: US13488270Application Date: 2012-06-04
-
Publication No.: US08691231B2Publication Date: 2014-04-08
- Inventor: Raghida Bukhalid , Ulrik Nielsen , Shannon Werner , Jeffrey David Kearns
- Applicant: Raghida Bukhalid , Ulrik Nielsen , Shannon Werner , Jeffrey David Kearns
- Applicant Address: US MA Cambridge
- Assignee: Merrimack Pharmaceuticals, Inc.
- Current Assignee: Merrimack Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Jill Gorny Sloper, Esq.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; G01N33/567 ; A61K38/18 ; A61P35/00
Abstract:
Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
Public/Granted literature
Information query
